BioSig Technologies Retains Gilmartin Group for Investor Relations
Santa Monica, CA, Sept. 24, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that it has retained Gilmartin Group for strategic investor relations and communication services.
“We are delighted to engage the team at Gilmartin Group as investor relations advisors. BioSig places a high priority on shareholder value and I am confident that Gilmartin’s extensive experience in capital markets, combined with their deep expertise in the healthcare technology sector makes them an ideal partner as we seek to raise visibility of BioSig within the investment community,” stated Mr. Kenneth Londoner, Chairman and CEO of BioSig Technologies.
"This is a very exciting time for us. We have built a strong balance sheet, world-class IP, a leadership team with deep clinical and commercial expertise, and the support of several leading medical centers of excellence. Now with the recent FDA clearance of our PURE EP™ System and the commencement of trading on the Nasdaq stock exchange, we feel it appropriate to elevate and bolster our investor relations program and look forward to partnering with the team at Gilmartin IR,” added Londoner.
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for its PURE EP™ System.
About Gilmartin Group
Gilmartin Group is a strategic advisory firm that provides comprehensive service offerings throughout the lifespan of its client companies. The team at Gilmartin has deep experience in Capital Markets, Investor Relations, Corporate Communications and Business Development / Strategic Advisory services. The firm’s professionals have spent their careers on Wall Street with backgrounds in Equity Research, Investment Banking and Equity Capital Markets. They bring that experience and expertise to clients to create durable shareholder value. More information can be found on the company’s website at http://gilmartinir.com/clients/.
Contact: Natasha Drapeau BioSig Technologies, Inc. Executive Vice President 12600 Hill Country Blvd R-275 Austin, TX 78738 firstname.lastname@example.org 512-329-2643
Released September 24, 2018